CurrentCapital BluecrossPolicy MP 5.055

Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast Conserving Surgery

Defines Capital Blue Cross medical policy MP 5.055 addressing use of handheld radiofrequency spectroscopy devices (e.g., MarginProbe) for intraoperative assessment of surgical margins during lumpectomy/breast-conserving surgery, including coding and benefit variation notes.

Policy Summary

PayerCapital Bluecross

PolicyHandheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins During Breast Conserving Surgery

Policy CodePolicy MP 5.055

Change TypeConsensus review; no change

Effective Date07/01/2025

Next Review Date

Key ActionConfirm the service is a covered benefit under the member's specific health benefit plan; the existence of this medical policy does not guarantee coverage.

SourceLink

POLICY UPDATE CHANGES

02/14/2025 Consensus review; No change to policy statement.

07/01/2025 Effective date listed for policy rationale section.

1Primary CPT code listed as not covered

InvestigationalCoverage stance

MultipleSupporting references

Policy MP 5.055 addresses the use of handheld radiofrequency spectroscopy (e.g., MarginProbe) for intraoperative assessment of surgical margins during breast‑conserving surgery. Capital Blue Cross considers this technology Investigational (coverage stance: Investigational / not covered for this purpose). Effective date: 2025-07-01. Last review: 2025-02-14.

Policy summary

Policy numberMP 5.055

Effective date2025-07-01

Last review2025-02-14

Coverage stanceInvestigational

Primary CPT codes not covered (count)1

Medical-Necessity Criteria

Medical Necessity Determination

Policy statement:

Handheld radiofrequency spectroscopy for intraoperative assessment of surgical margins during breast-conserving surgery is considered investigational.

Insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Not Covered / Experimental

The policy determination is that handheld radiofrequency spectroscopy is investigational because available evidence is insufficient to demonstrate net health benefit. Diagnostic studies report moderate sensitivity and poor specificity, and a randomized trial did not show a statistically significant reduction in re‑excision rates. Although the device has FDA PMA approval (2013) as an adjunctive intraoperative tool, the totality of evidence is judged insufficient to support coverage.

Provider Actions

Documentation Required

Benefit verification required

Confirm the service is a covered benefit under the member's specific health benefit plan; the existence of this medical policy does not guarantee coverage.

Billing Rule

Do not bill as covered without benefit

Although CPT code 0546T exists, the service is designated investigational and not covered per this policy; identification of a code does not denote coverage.

0546T

Background

MarginProbe is a handheld radiofrequency spectroscopy probe intended to analyze dielectric properties of excised lumpectomy specimens and provide per‑touch positive/negative readings to help identify positive margins and potentially reduce re‑excision. The device is indicated for use on the main ex‑vivo lumpectomy specimen as an adjunct to standard intraoperative methods. MarginProbe received FDA PMA approval in January 2013. The evidence base includes randomized and observational studies; overall quality shows moderate sensitivity, poor specificity, and inadequate data on local recurrence or long‑term outcomes, leaving insufficient evidence to establish clinical benefit.

Definition

TermMarginProbe / handheld radiofrequency spectroscopy

DefinitionA handheld probe that measures dielectric properties of excised breast tissue to identify likely malignant tissue at specimen margins, providing per-touch positive/negative readings; intended for use on main ex-vivo lumpectomy specimen only.

This policy defines Capital Blue Cross medical policy MP 5.055 and addresses use of handheld radiofrequency spectroscopy devices (e.g., MarginProbe) for intraoperative surgical margin assessment during lumpectomy/breast‑conserving surgery, including coding and benefit variation notes. Capital Blue Cross administers the policy and benefit determinations depend on the member's specific health benefit plan.

Evidence Summary

Evidence summary

Randomized trial outcomeDifference in re-excision rates not statistically significant; trial had methodological limitations

Diagnostic performanceModerate sensitivity and poor specificity reported

Evidence conclusionInsufficient to determine effects on health outcomes; investigational

Revision History

02/14/2025revisedLatest

Consensus review; No change to policy statement. References reviewed/updated; administrative updates noted previously (11/20/2024) removed NCCN statement.

07/01/2025added

Effective date listed for policy rationale section. Effective Date: 7/1/2025.